Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicotine gum

This article was originally published in The Tan Sheet

Executive Summary

U.S. Supreme Court denies SmithKline requested review of a New York federal appellate decision allowing Watson Pharmaceuticals to market private label OTC nicotine polacrilex gum. The high court Oct. 2 declines SB's request to consider claims the audiocassette and user's guide for Watson's private label gum infringe the Nicorette copyright. Watson began selling the gum after the Second Circuit's April ruling that the Hatch/Waxman Amendments "require generic drug sellers to use labeling that may infringe a copyright in the label of a pioneer drug" (1"The Tan Sheet" April 10, p. 8)

You may also be interested in...



Hatch/Waxman Act Allows Potential Copyright Infringement - Court

A New York City federal appeals court unanimously ruled in favor of Watson Pharmaceuticals April 4, lifting a preliminary injunction against the sale of its generic OTC nicotine polacrilex gum and dismissing SmithKline Beecham Consumer Healthcare's copyright infringement action.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel